These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 25759847)

  • 1. Fas ligand DNA enhances a vaccination effect by coadministered DNA encoding a tumor antigen through augmenting production of antibody against the tumor antigen.
    Zhong B; Ma G; Sato A; Shimozato O; Liu H; Li Q; Shingyoji M; Tada Y; Tatsumi K; Shimada H; Hiroshima K; Tagawa M
    J Immunol Res; 2015; 2015():743828. PubMed ID: 25759847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of DNA Encoding the Interleukin-27 Gene Augments Antitumour Responses through Non-adaptive Immunity.
    Li Q; Sato A; Shimozato O; Shingyoji M; Tada Y; Tatsumi K; Shimada H; Hiroshima K; Tagawa M
    Scand J Immunol; 2015 Oct; 82(4):320-7. PubMed ID: 26095954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen.
    Tüting T; Gambotto A; Robbins PD; Storkus WJ; DeLeo AB
    Gene Ther; 1999 Apr; 6(4):629-36. PubMed ID: 10476222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fas ligand-expressing tumors induce tumor-specific protective immunity in the inoculated hosts but vaccination with the apoptotic tumors suppresses antitumor immunity.
    Tada Y; O-Wang J; Wada A; Takiguchi Y; Tatsumi K; Kuriyama T; Sakiyama S; Tagawa M
    Cancer Gene Ther; 2003 Feb; 10(2):134-40. PubMed ID: 12536202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination.
    Ni J; Schirrmacher V; Fournier P
    Vaccine; 2010 Oct; 28(42):6891-900. PubMed ID: 20709006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice.
    Lladser A; Párraga M; Quevedo L; Carmen Molina M; Silva S; Ferreira A; Billetta R; G Quest AF
    Immunobiology; 2006; 211(1-2):11-27. PubMed ID: 16446167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogene therapy.
    Lichtor T; Glick RP
    Adv Exp Med Biol; 2012; 746():151-65. PubMed ID: 22639166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice.
    Song K; Chang Y; Prud'homme GJ
    Gene Ther; 2000 Sep; 7(18):1527-35. PubMed ID: 11021590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigen-specific induction of peripheral T cell tolerance in vivo by codelivery of DNA vectors encoding antigen and Fas ligand.
    Georgantas RW; Leong KW; August JT
    Hum Gene Ther; 2000 Apr; 11(6):851-8. PubMed ID: 10779162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA interference-mediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency.
    Huang B; Mao CP; Peng S; Hung CF; Wu TC
    Hum Gene Ther; 2008 Aug; 19(8):763-73. PubMed ID: 18627219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity.
    Westermann J; Nguyen-Hoai T; Baldenhofer G; Höpken UE; Lipp M; Dörken B; Pezzutto A
    Cancer Gene Ther; 2007 Jun; 14(6):523-32. PubMed ID: 17384577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo responses to vaccination with Mage-b, GM-CSF and thioglycollate in a highly metastatic mouse breast tumor model, 4T1.
    Gravekamp C; Leal B; Denny A; Bahar R; Lampkin S; Castro F; Kim SH; Moore D; Reddick R
    Cancer Immunol Immunother; 2008 Jul; 57(7):1067-77. PubMed ID: 18094967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with FasL-/TCL plus MHSP65 induces improved anti-lung cancer immunity in mice.
    Dong B; Dai G; Ding Y; Wang B; Zhang S
    Int Immunopharmacol; 2018 Feb; 55():306-311. PubMed ID: 29310106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-Specific CD8
    Cáceres-Morgado P; Lladser A
    Methods Mol Biol; 2021; 2197():225-239. PubMed ID: 32827140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination of apoptotic Fas ligand-expressing tumors decreased antitumor responses by enhanced production of immunosuppressive cytokines.
    Wada A; Tada Y; Shimozato O; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
    Anticancer Res; 2005; 25(1A):299-303. PubMed ID: 15816551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigen-specific CD8+ T lymphocytes generated from a DNA vaccine control tumors through the Fas-FasL pathway.
    Cheng WF; Lee CN; Chang MC; Su YN; Chen CA; Hsieh CY
    Mol Ther; 2005 Nov; 12(5):960-8. PubMed ID: 15979942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
    Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
    Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.
    Moeini S; Saeidi M; Fotouhi F; Mondanizadeh M; Shirian S; Mohebi A; Gorji A; Ghaemi A
    Arch Virol; 2017 Feb; 162(2):333-346. PubMed ID: 27699512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
    LaTemple DC; Abrams JT; Zhang SY; Galili U
    Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.